about
Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Gist and verbatim communication concerning medication risks/benefits.Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritisComplicated Whipple's disease and endocarditis following tumor necrosis factor inhibitorsRole of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in IndiaDoes non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysisPeriodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population.Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.TNF inhibition for ophthalmic indications: current status and outlook.Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach.Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis.Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.Etanercept: a review of its use in autoimmune inflammatory diseases.A clinical perspective on the role of chronic inflammation in gastrointestinal cancer.Sirukumab : a novel therapy for lupus nephritis?Safety issues and concerns of new immunomodulators in rheumatology.Genetic of uveitis.A fatal case of disseminated chronic Q fever: a case report and brief review of the literature.Cutaneous side effects of TNF-alpha inhibitors.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Medication risk communication during rheumatology office visits.Nebenwirkungen von TNF-alpha-Inhibitoren am Hautorgan.Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Refractory necrotizing scleritis successfully treated with adalimumab.Tocilizumab: A Review in Rheumatoid Arthritis.[Secondary immunodeficiency in rheumatological diseases].Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis.
P2860
Q30725001-3307FABD-48C6-403E-8F15-854B6F86277CQ33778719-0C7272F4-F9CB-4AFF-8BC3-218714B46852Q33906679-0154432D-ED75-4162-B4B5-A08BC1E14A28Q34411088-50FA7F08-1D9E-4A8E-B228-63CCF61DBC32Q34780133-2CDEABD7-31ED-47AD-B87C-75156F5BD80CQ35164284-DC2FD76B-4FE8-4194-80DD-4E7E48239CA6Q35174817-A596251B-5AA8-4007-AA13-19BBCF3399BDQ35705082-48A1E384-C4E6-4560-B7BA-0823DE941062Q36216042-3B0F52D0-64D6-4435-8A43-D51559962DDCQ36267592-026447A2-4243-4347-B7A3-146403859BEAQ36300250-7B6E62A2-0888-4D4D-B51C-3F3268F2B7ECQ37627252-D5326441-2EF6-4266-BE79-D92C1C9E218DQ37654774-7B73DD63-FB30-455F-A258-88F2A8661592Q37662745-D95A1DC2-D024-4C20-B081-7F53998954C0Q38097327-C64654B7-AD42-48E0-BCB7-3687FF4E4601Q38118781-96B6C8C0-54B5-446B-9212-B3C6AC1ED593Q38161956-F7564D41-21DD-4D8F-86C0-5E9853EF26D9Q38164315-3B30CC24-C7AC-4053-B798-5CA9C86D8B58Q38182440-ADAA4F7B-BE7A-4C4B-A591-483EEF8E4140Q38199165-CCD30CC1-1C25-454D-858E-2611E0EB22F5Q38219589-9D80E165-4E07-41B5-BA67-F4755566B2B6Q38230740-C65C2282-2CE0-4AC2-8197-8F5309873A24Q38241837-ED2E1E2E-32FF-4033-83AD-41EEDBEE55D6Q38246130-123F3BA0-A5A8-45CE-B8E1-91DD8A4EB2C1Q38292111-58C3EDC9-DA19-433A-A5D1-B85B63FF967AQ38603345-9B17766C-C152-4F58-A245-F30A41F8A97CQ38759759-292945AD-6B20-41BB-A723-1EFF77817FC8Q38933554-9129009F-3431-4D58-81A5-D44E9686678CQ38972531-5258812F-0729-482C-B970-BD77C90780B3Q39042940-502A4BD6-4146-438E-84E0-25A953185DE6Q39151827-AC7BB57E-E363-4E7C-AA2D-21EE37CED1EAQ39158058-D7C3FA44-EF4F-46B6-84D7-854D0D624CFEQ39729881-B6ADD10F-7412-4602-9FB9-E19FC8D98F6AQ40068342-3F179606-DD1A-49A0-B989-262360CCBBD9Q40598586-87D58F6A-83CD-4996-97DB-165E9CE896ADQ41176187-E8C9C1EF-150E-4410-9719-ED9A64128353Q42384558-7DA7ECD0-A70B-4774-98AE-6D678E2D08A9Q43280791-899E06B4-2839-4332-9FEC-B2EA30C3E7B2Q44975901-44C889D3-9FD6-4D1C-AF84-755F3B8CFC74Q45903141-6D8C2ED5-38B8-41A7-A4E8-DC5135AF1846
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overview of safety of non-biologic and biologic DMARDs.
@en
type
label
Overview of safety of non-biologic and biologic DMARDs.
@en
prefLabel
Overview of safety of non-biologic and biologic DMARDs.
@en
P2860
P356
P1433
P1476
Overview of safety of non-biologic and biologic DMARDs.
@en
P2093
Eric M Ruderman
P2860
P304
P356
10.1093/RHEUMATOLOGY/KES283
P478
51 Suppl 6
P577
2012-12-01T00:00:00Z